Background: Acinetobacter baumannii is intrinsically resistant to fosfomycin; however, the mechanisms underlying this resistance are poorly understood.
Introduction
The global emergence of MDR Acinetobacter baumannii has complicated the clinical management of infections caused by this microorganism. Few treatment options with appropriate antimicrobial activity remain for infections caused by A. baumannii strains with resistance to multiple antibiotic classes. Reports describing infections caused by pandrug-resistant A. baumannii are of particular concern.
1,2 For these reasons, there is a clear need for the development of novel antimicrobials for the treatment of MDR A. baumannii. Unfortunately, efforts aimed at developing antimicrobials with activity against Gram-negative species over the preceding decades have yielded few new compounds. In this context, therapeutic alternatives based on existing antibiotics that have not been used in the treatment of MDR A. baumannii may contribute to improving the clinical management of these infections.
Fosfomycin was first described in the 1960s, and has demonstrated antimicrobial activity against multiple clinically relevant Gram-negative and Gram-positive species. 3 Its mechanism of antimicrobial action is the inhibition of a key step in the de novo peptidoglycan biosynthesis pathway. In Escherichia coli, upon gaining access to the cytoplasm via the transporters GlpT and UhpT, fosfomycin irreversibly binds to MurA (a UDP-GlcNAc enopyruvyl transferase), which catalyses the first committed step in peptidoglycan biosynthesis through the synthesis of UDP-GlcNac-3-O-enolpyruvate from UDP-GlcNAc and phosphoenolpyruvate.
3 A. baumannii is intrinsically resistant to fosfomycin, with multiple studies demonstrating non-susceptibility in clinical isolates. A study including 34 MDR A. baumannii clinical isolates demonstrated fosfomycin MICs 128 mg/L for all strains. 4 In a separate study the fosfomycin MIC 90 for 30 A. baumannii clinical isolates was .512 mg/L. 5 Additionally, two recent studies have also indicated high levels of fosfomycin resistance in A. baumannii with resistance rates of 97% in collections of clinical isolates. 6, 7 In spite of multiple studies showing low fosfomycin susceptibility in clinical isolates of A. baumannii, little is known regarding the mechanisms underlying this apparent intrinsic resistance. A. baumannii encodes a functional MurA enzyme that is inhibited by fosfomycin in in vitro assays, 8 suggesting that resistance is likely not due to lack of activity of fosfomycin against its bacterial target. Fosfomycin resistance in other Gram-negative bacterial species can occur owing to mutations in the two transporters, GlpT and UhpT, and in genes that regulate their transcription. [9] [10] [11] [12] However, this mechanism has not been explored in A. baumannii. The fosA gene, which encodes a glutathione S-transferase that inactivates fosfomycin through its conjugation to glutathione, was recently associated with fosfomycin resistance in multiple Gram-negative species. 13 In this study, sequence analysis of A. baumannii genomes failed to identify a fosA homologue in A. baumannii. Recently, a major facilitator superfamily transporter, AbaF, was shown to contribute to fosfomycin resistance in A. baumannii through facilitating efflux of fosfomycin out of the bacterial cell.
14 Importantly, the abaF gene was expressed in 22 of 24 of the clinical isolates tested in that study. In a separate study, mutation of the abrp gene, which encodes a C13 peptidase, was shown to result in increased membrane permeability and increased susceptibility to multiple antibiotics, including fosfomycin. 15 In this context, we aimed to gain additional understanding of the low susceptibility to fosfomycin that is observed in A. baumannii by screening library of .9000 transposon mutants in order to identify genes that contribute to resistance.
Materials and methods

Construction of an A. baumannii transposon mutant library
The A. baumannii strain ATCC 17978 was used for library construction. For preparation of electrocompetent cells, a 100 mL culture of the ATCC 17978 strain in LB medium was grown to the late exponential phase (OD 600 of 0.6-0.8) at 37 C with shaking at 160 rpm. Cells were harvested by centrifugation and washed three times with 20 mL of ice-cold sterile water. After the last wash, the resulting cell pellet was suspended in 500 lL of 10% glycerol (in sterile water), and 100 lL aliquots were stored at #80 C until use. For electroporation, 33 ng (1 lL) of the EZ-Tn5 ,R6Kcori/KAN-2.Tnp Transposome (Epicentre Technologies) was added to 100 lL of electrocompetent cells and electroporated at a capacitance of 25 lF and a voltage of 1.2 kV. Immediately after electroporation, 900 lL of SOC medium was added to the cells, followed by incubation at 37
C for 1 h. Subsequently, 3 mL of LB medium was added to the cell suspension and 100 lL aliquots were plated on LB agar plates containing 10 mg/L kanamycin. After incubation at 37 C for 24 h, all kanamycin-resistant colonies were selected and replated on LB plates containing 10 mg/L kanamycin. Each transposon mutant was transferred to a well of a 96-well plate containing LB with 10 mg/L kanamycin and incubated at 37 C for 3 h. Subsequently, 100 lL of LB supplemented with 30% of glycerol was added to each well, and the plates were stored at #80 C until use. In total, two rounds of electroporation resulted in the isolation of 9000 transposon mutants.
Identification of genes involved in fosfomycin resistance
The entire mutant library was screened on Mueller-Hinton agar (Sigma) with 32 mg/L fosfomycin by individually plating mutants using a 96-pronged replicator. Screening of the library was carried out in the absence of glucose-6-phosphate. This subinhibitory concentration of fosfomycin (MIC of fosfomycin for ATCC 17978 . 1024 mg/L) was selected since it results in robust growth of the ATCC 17978 strain on solid media, thus permitting the visual identification of mutants with increased fosfomycin susceptibility. The plated mutants were incubated at 37 C for 24 h, and mutants exhibiting no or markedly reduced growth in the presence of fosfomycin were compared with control plates without antibiotic and were selected for further study. In order to identify the gene disrupted by transposon mutagenesis, genomic DNA was isolated from selected mutants using a QIAmp DNA Mini Kit (Qiagen), and 2 lg of genomic DNA was randomly fragmented with EcoRI (New England Biolabs). After enzyme inactivation at 65 C for 20 min, 10 lL of digested DNA was self-ligated using 0.5 lL of T4 DNA Ligase (New England Biolabs) in 20 lL total volume for 4 h at room temperature. The reaction was terminated by inactivating the T4 DNA Ligase by heating at 70 C for 10 min. Seven microlitres of the ligation mix was transformed into E. coli S17-1 kpir by electroporation, and plated on LB agar supplemented with 30 mg/L kanamycin. Plasmid DNA was extracted from transformants using a DNA-spin Plasmid DNA Purification Kit (iNtRON Biotechnology), and the genomic DNA flanking the transposon insertion site was sequenced using the following primers: KAN-2 FP-1 Forward Primer (5 0 -ACCTACAACAAAGCTCTCATCAACC-3 0 ) and R6KAN-2 RP-1 Reverse Primer (5 0 -CTACCCTGTGGAACACCTACATCT-3 0 ). The transposon insertion sites were identified by comparing the obtained sequences with the ATCC 17978 genome sequence (accession number NZ_CP009257.1).
Antibiotic susceptibility testing
Fosfomycin MICs were determined by Etest (BioMérieux) on Mueller-Hinton agar plates. All other MICs were determined by broth microdilution according to CLSI guidelines. 16 E. coli ATCC 25922, E. coli ATCC 35218, Pseudomonas aeruginosa ATCC 27853 and Staphylococcus aureus ATCC 29213 were used as quality controls.
Construction of ampD and anmK mutants
Stable, in-frame deletion mutants were constructed in the A. baumannii ATCC 17978 strain by homologous recombination using a previously described protocol. 17 Briefly, for construction of Fosfomycin resistance in A. baumannii JAC the ampD deletion mutant (ATCC 17978 DampD::Kan), the 500 bp immediately upstream of the ampD ORF were amplified using the primers ampD Up Forward and ampD Up Reverse (Table 1) , and the 500 bp immediately downstream were amplified using the primers ampD Down Forward and ampD Down Reverse. The kanamycin resistance gene from the plasmid pKD4 was amplified using the primers Kanamycin Forward and Kanamycin Reverse, resulting in a PCR product with sequences overlapping the PCR fragments containing the sequences upstream and downstream of the ampD gene. The three PCR products were combined in a stitching PCR reaction, and 5 lg of the resulting construct was transformed into the ATCC 17978 strain by electroporation before selection on LB agar plates with 10 mg/L kanamycin. The anmK deletion mutant (ATCC 17978 DanmK::Kan) was constructed in the same way using the primers listed in Table 1 . All deletion mutants were confirmed by sequencing and maintained in 30 mg/L kanamycin. In order to complement the deletion mutants, the ampD and anmK reading frames and 200-400 bp upstream and downstream were amplified using the primers indicated in Table 1 . These fragments were cloned into the pUCp24 and introduced into the mutant strains by electroporation before selection on LB agar containing 10 mg/L gentamicin to create the complemented strains (ATCC 17978 DampD::Kan/pUCp24-ampD and ATCC 17978 DanmK::Kan/pUCp24-anmK). Deletion mutants were also transformed with the empty pUCp24 plasmid for use as controls (ATCC 17978 DampD::Kan/pUCp24 and ATCC 17978 DanmK::Kan/ pUCp24).
Growth curves
Strains were cultured in 20 mL of Mueller-Hinton broth overnight at 37 C, and subsequently diluted to 10 5 cfu/mL with MuellerHinton broth containing the indicated concentrations of fosfomycin. One-hundred and fifty microlitres of the cell suspension was added to each well of a 96-well plate and growth at 37 C was monitored over 24 h by measuring OD 600 every 30 min using an automated plate reader (M200 Infinite Pro, Tecan).
Cell permeability assay
The permeability of the WT and mutant strains was characterized using an ethidium bromide (EtBr) accumulation assay modified from a previous study. 18 Cells were re-suspended in PBS and adjusted to an OD 600 of 0.2. Aliquots of 95 lL were incubated for 10 min at 37 C. Then, 5 lL of EtBr was added to each cell suspension to obtain a final EtBr concentration of 2 mg/L. Fluorescence was measured at 120 min (k excite " 530 nm; k emit " 600 nm).
Peptidoglycan integrity assay
A previously described protocol for assessing peptidoglycan integrity by measuring susceptibility to lysozyme-mediated cell lysis was adapted for the present study. 19 Cells were resuspended in 10 mM HEPES (pH 7.5) and adjusted to an OD 600 of 2.3. Aliquots of 63 lL of the cell suspensions were added to 65 lL of HEPES buffer, 62 lL of 10 mM EDTA and 10 lL of 1 mg/mL lysozyme in a 96-well plate. Bacterial lysis was assessed over 1 h at 25 C by measuring the OD 600 every 2 min using an automated plate reader (M200 Infinite Pro, Tecan).
Statistical analysis
Differences in cell permeability were determined using the ANOVA test (GraphPad 6). A P value , 0.05 was considered significant.
Results
Identification of genes contributing to fosfomycin resistance in A. baumannii Screening of .9000 A. baumannii transposon mutants for increased susceptibility to fosfomycin resulted in the identification of mutants with decreased growth in the presence of 32 mg/L fosfomycin. Sequencing of the transposon insertion site revealed mutations in the genes encoding N-acetyl-anhydromuramyl-L-alanine amidase (ampD, ABO10540.2) and anhydro-Nacetylmuramic acid kinase (anmK, ABO10510.2). Interestingly, these genes encode enzymes involved in subsequent catalytic steps in the peptidoglycan recycling pathway (Figure 1) . AmpD cleaves the bond between anhMurNAc and the peptidoglycan peptide chain, resulting in the liberation of anhMurNAc. This molecule is the substrate of AnmK, a specific anhMurNAc kinase that generates MurNAc-P, which can then be used in the de novo peptidoglycan synthesis pathway. 20 Fosfomycin MICs for the ampD and anmK insertion mutants were 16-fold (MIC 64 mg/L) and 85-fold (12 mg/L) lower, respectively, than the fosfomycin MIC of the parental strain (1024 mg/L).
Effect of ampD and anmK mutation on susceptibility to fosfomycin
In order to study the roles of ampD and anmK in fosfomycin resistance, we generated in-frame deletion mutants for both genes in the ATCC 17978 strain (ATCC 17978 DampD::Kan and ATCC 17978 DanmK::Kan, respectively). The fosfomycin MIC for ATCC 17978 DampD::Kan was 24 mg/L (42-fold decrease compared with ATCC 17978), whereas the fosfomycin MIC for ATCC 17978 DanmK::Kan was 128 mg/L (8-fold decrease compared with ATCC 17978). For both mutant strains, complementation with a plasmid containing a WT copy of the deleted gene restored fosfomycin MICs to 1024 mg/L, whereas complementation with an empty plasmid did not result in increased MIC values (Tables 2 and 3, Figure 2 ). These results confirm the role of ampD and anmK in resistance to fosfomycin in A. baumannii.
To further characterize the effect of ampD and anmK deletion on susceptibility to fosfomycin, bacterial growth in the presence of 32 mg/L fosfomycin was assessed over 24 h. As can be seen in Fosfomycin resistance in A. baumannii JAC partially restored the growth defect observed in the presence of fosfomycin compared with growth of the complemented strains in medium without antibiotics (Figure 3c and d) . The ampD and anmK mutants containing an empty plasmid did not demonstrate restoration of growth in the presence fosfomycin compared with growth in medium without antibiotics (Figure 3e and f) .
Effect of ampD and anmK deletion on cell permeability and peptidoglycan integrity
Since both ampD and anmK are predicted to participate in the peptidoglycan recycling pathway, 20 we next wanted to determine how deletion of these genes affected membrane permeability and peptidoglycan integrity. In order to assess membrane permeability, an EtBr accumulation assay that has been described previously was employed. 18 As can be seen in Figure 4 (a), there were no significant differences in intracellular accumulation of EtBr between the parental and mutant strains, indicating that, at least in this assay, ampD and anmK deletions do not result in increased membrane permeability.
To assess the effect of ampD and anmK deletion on peptidoglycan integrity, an assay based on measuring cell lysis in the presence of lysozyme was employed. 19 As shown in Figure 4 (b), the OD 600 of the ATCC 17978 DampD::Kan culture was reduced by 32.4% over the 56 min incubation time, indicating significant cell lysis. In contrast, only minimal cell lysis was observed in cultures containing the parental (5.4%) and ATCC 17978 DanmK::Kan (6.6%) strains. The more marked effect on peptidoglycan integrity observed in the ATCC 17978 DampD::Kan strain is interesting given the greater reduction in fosfomycin MIC (Figure 1 ) and the greater reduction in growth in the presence of fosfomycin (Figure 2 ) compared with the ATCC 17978 DanmK::Kan strain. It should be noted, however, that decreased peptidoglycan integrity and increased fosfomycin susceptibility may not be directly linked.
Effect of ampD and anmK mutation on antibiotic susceptibility
We next wanted to determine how deletion of ampD and anmK in A. baumannii affected susceptibility to other clinically relevant antibiotics. MIC values were determined by broth microdilution for the 21 antibiotics listed in Tables 2 and 3 . The ATCC 17978 DampD::Kan strain was 8-fold more susceptible to cefepime than the parental strains, and the ATCC 17978 DanmK::Kan strain was slightly (4-fold) more resistant to gentamicin and rifampicin than the parental strain. Importantly, MIC values for the deletion mutants were within 2-fold of the parental strain for all other antibiotics tested. Taken together, these results indicate that deletion of ampD and anmK has little effect on antibiotics other than fosfomycin and cefepime in A. baumannii.
Discussion
The present study implicates ampD and anmK, both of which are involved in peptidoglycan recycling, in intrinsic fosfomycin Gil-Marqués et al.
resistance in A. baumannii. In E. coli, as well as other related Enterobacteriaceae species and many Gram-positive species, the initial steps of peptidoglycan recycling occur when endopeptidases and transglycosylases release anhydromuropeptides into the periplasm (Figure 1 ), where they are subsequently transported into the cytoplasm by AmpG. 21 In the cytoplasm, the anhydromuropeptide is hydrolysed by NagZ and AmpD to produce GlcNAc and anhydroMurNAc. [21] [22] [23] [24] The anhydroMurNAc is phosphorylated by AnmK to yield MurNAc-P, which is then converted to GlcNAc-6-P by an unknown enzyme, and NagK converts the GlcNAc directly to GlcNAc-6-P. [25] [26] [27] Through a series of enzymatic steps, GlcNAc-6-P is converted to UDP-GlcNAc, the substrate for fosfomycin's target, MurA. 20 Thus, in many Enterobacteriaceae and Gram-positive species, both de novo peptidoglycan synthesis and the peptidoglycan recycling pathway require the activity of MurA, explaining their susceptibility to fosfomycin.
A recent study by Gisin et al. 28 identified a salvage pathway within the peptidoglycan recycling system that bypasses the enzymatic step catalysed by MurA in Pseudomonas putida, which, similar to A. baumannii, demonstrates intrinsic resistance to fosfomycin. In this salvage pathway, the three enzymes MupP, AmgK and MurU convert the MurNAc-P derived from hydrolysis of anhydromuropeptides directly into UDP-MurNAc, without the activity of MurA and MurB (Figure 1; salvage pathway) . 28, 29 Gisin et al. 28 demonstrated that this salvage pathway was directly responsible for fosfomycin resistance in P. putida by showing that mutants lacking AmgK and MurU had increased susceptibility to fosfomycin. In a subsequent study by the same group, this salvage pathway was identified in P. aeruginosa, and shown to contribute to intrinsic fosfomycin resistance in this species as well. 30 Upon identifying genes involved in peptidoglycan recycling in the present study, we searched for MupP, AmgK and MurU homologues in the A. baumannii 17978 complete genome, and found homologues for each of the three enzymes of the salvage pathway (accession numbers ABO10530.2, ABO11975.2 and ABO11976.2). Although not directly tested here, this finding strongly suggests that this salvage pathway is present in A. baumannii, and may explain the low susceptibility to fosfomycin observed in this species. It is interesting to note that none of the three genes in the salvage pathway was identified in the present study as contributing to fosfomycin resistance. However, the genes encoding the enzymes that act directly upstream of the salvage pathway during peptidoglycan recycling, AmpD and AnmK, were shown here to contribute to fosfomycin resistance. Taken together, these findings suggest that the availability of substrates produced in enzymatic steps prior to the salvage pathway, specifically substrates produced by AmpD and AnmK, affect the ability to bypass MurA functions during peptidoglycan recycling.
The data presented here implicating AmpD and AnmK in fosfomycin resistance in A. baumannii are supported by previous studies demonstrating that these proteins contribute to fosfomycin resistance in Pseudomonas species. In the previously mentioned study by Gisin et al., 28 a P. putida mutant lacking AnmK showed increased susceptibility to fosfomycin compared with the parental WT strain. Additionally, in a separate study, an anmK mutant of the P. aeruginosa PA14 strain demonstrated 4-fold increased susceptibility to fosfomycin compared with the parental strain. 30 With respect to AmpD, a recent study by Hamou-Segarra et al. 31 demonstrated that a triple knockout of the three ampD genes in P. aeruginosa strain PA01 showed a 4-fold increase in fosfomycin susceptibility compared with the WT strain. It is important to note that P. aeruginosa produces three AmpD homologues, whereas sequence analysis of A. baumannii suggests that only a single gene encoding AmpD is present. In the present study, the ampD mutant appeared to demonstrate a more marked phenotype than the anmK mutant, as demonstrated by a larger decrease in fosfomycin MIC (42-fold versus 8-fold) and increased susceptibility to lysozyme in the peptidoglycan integrity assay. This may be because AmpD participates in the initial hydrolysis of anhydromuropeptides in the cytoplasm, yielding GlcNAc and anhMurNAc, which can both be Fosfomycin resistance in A. baumannii JAC converted to GlcNAc-6-P and subsequently to UDP-GlcNAc, the substrate of MurA (Figure 1) . Thus, lack of AmpD function may affect the yield of UDP-GlcNAc derived from both GlcNAc and anhMurNAc. On the other hand, AnmK together with an unknown enzyme catalyses the conversion of anhMurNAc to GlcNAc-6-P in an enzymatic step subsequent to the hydrolysis of the anhydromuropeptide by AmpD. Thus, lack of AnmK function likely only affects the yield of UDP-GlcNAc derived from anhMurNAc ( Figure  1 ). It is interesting to note that in P. aeruginosa inactivation of ampD genes leads to b-lactam resistance owing to increased expression of the chromosomally encoded AmpC b-lactamase.
32,33
This has not been shown to occur in A. baumannii.
The results presented here suggest that pharmacological inhibition of the peptidoglycan recycling pathway could increase susceptibility to fosfomycin in A. baumannii, presenting the possibility that combination treatment with fosfomycin together with inhibitors of enzymes involved in this pathway could be an effective treatment. It is important to note that the MIC for the ampD mutant in the present study is 24 mg/L, which is below the fosfomycin breakpoint for susceptibility in E. coli. 16 The previously mentioned study by HamouSegarra et al. 31 demonstrated that pharmacological inhibition of NagZ, one of the enzymes involved in cytoplasmic hydrolysis of anhydromuropeptides, resulted in increased susceptibility to fosfomycin in P. aeruginosa. Interestingly, homologues of both NagZ and AmpG (the anhydromuropeptide transporter involved in peptidoglycan recycling) are present in the ATCC 17978 genome (accession numbers ABO10945 and ABO12845, respectively). Given the increasing incidence of infections caused by A. baumannii strains with resistance to multiple classes of antibiotics, pharmacological inhibition of enzymes/transporters involved in peptidoglycan recycling may be an approach that warrants further study. As a first step, future studies characterizing the susceptibility of ampD and anmK mutants to fosfomycin in animal models of infection would be of interest. In summary, this is the first study to demonstrate that genes involved in peptidoglycan recycling contribute to intrinsic resistance in A. baumannii. These results may therefore point to novel treatment approaches for infections caused by this microorganism.
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